AZD6244 is an orally available, potent, selective, ATP-uncompetitive inhibitor of MEK1/2, with pre-clinical activity in BRAF mutation-positive (BRAF+) and RAS mutation-positive tumour models (Yeh et al, 2007). Here, BRAF is linked to neoplasm.